Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

199.58 +3.65 (+1.86%)
Official Closing Price Updated: 7:00 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
News headline image
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse? ↗
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside 
Via Benzinga
News headline image
Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'? ↗
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the key items and numbers to watch. 
Via Benzinga
Topics Stocks
News headline image
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression ↗
FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials. 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Looking Into Johnson & Johnson's Recent Short Interest ↗
 
Via Benzinga
News headline image
2 Beaten-Down Dividend Stocks to Buy in 2025 ↗
Via The Motley Fool
News headline image
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. ↗
Via The Motley Fool
News headline image
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗
Via The Motley Fool
Topics Stocks
News headline image
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever ↗
Via The Motley Fool
News headline image
Healthcare And Biotech Stocks Lag The Market Again ↗
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals. 
Via Benzinga
News headline image
MarketBeat Week in Review – 01/13 - 01/17
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally 
Via MarketBeat
Topics Economy Energy
News headline image
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond ↗
Via The Motley Fool
News headline image
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade ↗
This magnificent company has been paying a continuous dividend to its shareholders since 1816. 
Via The Motley Fool
News headline image
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
News headline image
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
News headline image
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive 
Via MarketBeat
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗
These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors. 
Via The Motley Fool
News headline image
10 One Decision Stocks To Buy Now ↗
The following 10 one decision stocks have increased their dividends for over 25 years, making them Dividend Aristocrats. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Got $200? 2 Dividend Stocks to Buy and Hold Forever ↗
These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock. 
Via The Motley Fool
News headline image
What Lies Ahead In 2025? Slower Growth, More Volatility ↗
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
News headline image
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty ↗
ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts and biotech recovery delays. 
Via Benzinga
News headline image
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On? ↗
Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company. 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
News headline image
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal ↗
The deal values the smaller biotech company at a 39% premium to last week's closing price. 
Via Investor's Business Daily
News headline image
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism ↗
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million... 
Via Stocktwits
News headline image
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
From Johnson & Johnson
Via Business Wire
News headline image
A Look At Dividend Kings ↗
In this video, we dive deep into 'Dividend Kings.' These are elite companies that have consistently increased their dividends for 50+ years. 
Via Talk Markets
Topics ETFs Stocks / Equities
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.